About AnaCardio
AnaCardio is a company based in Sweden founded in 2017 by Lars Lund.. AnaCardio has raised $36.49 million across 4 funding rounds from investors including Karolinska Development, Novo Holdings and Pureos Bioventures. AnaCardio offers products and services including AC01 and Ghrelin-Based Agents. AnaCardio operates in a competitive market with competitors including AskBio, Inotrem, Juvenescence, Mission Therapeutics and Nuevocor, among others.
- Headquarter Sweden
- Founders Lars Lund
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Anacardio Ab
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$36.49 M (USD)
in 4 rounds
-
Latest Funding Round
$19 M (USD), Series A
Jan 09, 2025
-
Investors
Karolinska Development
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AnaCardio
AnaCardio offers a comprehensive portfolio of products and services, including AC01 and Ghrelin-Based Agents. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug that increases heart contractility for heart failure patients
Novel compounds targeting impaired cardiac function in heart failure
Unlock access to complete
Unlock access to complete
Funding Insights of AnaCardio
AnaCardio has successfully raised a total of $36.49M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $19 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $19.0M
- First Round First Round
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2025 | Amount | Series A - AnaCardio | Valuation | Novo Holdings , Pureos Bioventures | |
| Sep, 2022 | Amount | Series A - AnaCardio | Valuation | Flerie , Industrifonden | |
| Feb, 2022 | Amount | Series A - AnaCardio | Valuation | Karolinska Development |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AnaCardio
AnaCardio has secured backing from 11 investors, including venture fund and angel investors. Prominent investors backing the company include Karolinska Development, Novo Holdings and Pureos Bioventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Venture capital is invested in innovative drug development companies.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AnaCardio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AnaCardio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Anacardio Comparisons
Competitors of AnaCardio
AnaCardio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AskBio, Inotrem, Juvenescence, Mission Therapeutics and Nuevocor, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction
|
|
| domain | founded_year | HQ Location |
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health
|
|
| domain | founded_year | HQ Location |
Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response
|
|
| domain | founded_year | HQ Location |
Gene therapies for cardiovascular disease treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Anacardio
Frequently Asked Questions about AnaCardio
When was AnaCardio founded?
AnaCardio was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Where is AnaCardio located?
AnaCardio is headquartered in Sweden.
Who is the current CEO of AnaCardio?
Patrik Stromberg is the current CEO of AnaCardio.
Is AnaCardio a funded company?
AnaCardio is a funded company, having raised a total of $36.49M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3.58M, raised on Jun 17, 2021.
What does AnaCardio do?
AnaCardio was established in 2017 in Sweden as a biotechnology firm focused on cardiovascular therapeutics. An intravenous endogenous peptide hormone has been developed to enhance cardiac contractility and improve clinical outcomes for heart failure patients. Operations center on drug development in the pharmaceutical sector, with leadership provided by founder Lars Lund and CEO Patrik Stromberg. The companys domain is anacardio.com.
Who are the top competitors of AnaCardio?
AnaCardio's top competitors include Juvenescence, AskBio and Mission Therapeutics.
What products or services does AnaCardio offer?
AnaCardio offers AC01 and Ghrelin-Based Agents.
Who are AnaCardio's investors?
AnaCardio has 11 investors. Key investors include Karolinska Development, Novo Holdings, Pureos Bioventures, Sound Bioventures, and Flerie.